Sunnybrook Health Sciences Centre, Toronto, ON.
Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON.
Curr Oncol. 2014 Feb;21(1):44-50. doi: 10.3747/co.21.1871.
Myelodysplastic syndromes (mdss) constitute a heterogeneous group of malignant hematologic disorders characterized by marrow dysplasia, ineffective hematopoiesis, peripheral blood cytopenias, and pronounced risk of progression to acute myeloid leukemia. Azacitidine has emerged as an important treatment option and is recommended by the Canadian Consortium on Evidence-Based Care in mds as a first-line therapy for intermediate-2 and high-risk patients not eligible for allogeneic stem cell transplant; however, practical guidance on how to manage patients through treatment is limited. This best practice guideline provides recommendations by a panel of experts from Canadian centres of excellence on the selection and clinical management of mds patients with azacitidine. Familiarity with the referral process, treatment protocols, dose scheduling, treatment expectations, response monitoring, management of treatment breaks and adverse events, and multidisciplinary strategies for patient support will improve the opportunity for optimizing treatment outcomes with azacitidine.
骨髓增生异常综合征（MDS）是一组异质性恶性血液病，其特征为骨髓增生异常、无效造血、外周血细胞减少以及向急性髓系白血病进展的风险明显增加。阿扎胞苷已成为一种重要的治疗选择，加拿大 MDS 循证护理联盟推荐其作为不适合异体干细胞移植的中危-2 及高危患者的一线治疗药物；然而，关于如何在治疗过程中管理患者的实用指南非常有限。本最佳实践指南由加拿大卓越中心的专家组提供，涉及阿扎胞苷治疗 MDS 患者的选择和临床管理建议。熟悉转诊流程、治疗方案、剂量安排、治疗预期、反应监测、治疗中断和不良事件的管理以及患者支持的多学科策略，将提高优化阿扎胞苷治疗效果的机会。
